Effect of Stimulant Drugs on Social Perception

Phase 1

Completed

• Conditions: Healthy; MDMA ('Ecstasy')
• Interventions: Drug: 3,4-Methylenedioxymethamphetamine; Drug: methamphetamine

• Registration Number: NCT03790618
• Lead Sponsor: University of Chicago

Brief Summary

The study will improve our understanding of the "prosocial" effects of ± 3,4-Methylenedioxymethamphetamine (MDMA), relative to a prototypical stimulant, methamphetamine (MA). The investigators seek to characterize the "uniquely social" effects of MDMA.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06-01
• Primary Completion: 2018-08-01
• Study Completion: 2018-08-01
• Study First Submitted: 2018-11-30
• Study First Submitted QC: 2018-12-28
• Study First Posted: 2018-12-31
• Results First Submitted: 2022-06-14
• Status Verified: 2023-03
• Results First Submitted QC: 2023-03-29
• Last Update Submitted: 2023-03-29
• Results First Posted: 2024-01-05
• Last Update Posted: 2024-01-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• High school degree
• English fluency
• Healthy
• Has used MDMA

Exclusion Criteria

• Pregnant or trying to become pregnant
• Any medical or psychiatry condition

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Low dose MDMA	3,4-Methylenedioxymethamphetamine	Subjects will attend one session during which they will receive 0.75mg/kg MDMA.
Placebo	3,4-Methylenedioxymethamphetamine	Subjects will attend one session during which they will receive a placebo capsule.
Placebo	methamphetamine	Subjects will attend one session during which they will receive a placebo capsule.
Low dose MDMA	methamphetamine	Subjects will attend one session during which they will receive 0.75mg/kg MDMA.
High dose MDMA	3,4-Methylenedioxymethamphetamine	Subjects will attend one session during which they will receive 1.5mg/kg MDMA.
Methamphetamine	3,4-Methylenedioxymethamphetamine	Subjects will attend one session during which they will receive 20mg methamphetamine.
High dose MDMA	methamphetamine	Subjects will attend one session during which they will receive 1.5mg/kg MDMA.
Methamphetamine	methamphetamine	Subjects will attend one session during which they will receive 20mg methamphetamine.

Primary Outcome Measures

Name	Time	Method
Responses to Affective Touch	End of study (time 0 and approximately six weeks later)	Participants will complete an affective touch task during which time they will rate pleasantness of touch on a likert scale of 1-7, with higher scores indicating greater ratings of pleasantness

Trial Locations

Locations (1)

University of Chicago; 🇺🇸 Chicago, Illinois, United States